Claims

1. At least one compound chosen from

(3aR, 6aR)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aS,6aS)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aR,6aR)-N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-1-methyl-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aS,6aS)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aR,6aR)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aS,6aS)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide; and

(3aR,6aR)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide,

and/or at least one pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one compound chosen from

(3aR, 6aR)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aS,6aS)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aR,6aR)-N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-1-methyl-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aS,6aS)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aR,6aR)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;

(3aS,6aS)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide; and

(3aR,6aR)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin
-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide,
and/or at least one pharmaceutically acceptable salt thereof.

3. A method of treating cancer responsive to inhibition of overexpression and/or overactivity of epidermal growth factor receptor, comprising administering to a subject in need thereof an effective amount of at least one compound chosen from
(3aR, 6aR)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-
methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;
(3aS,6aS)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-
methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;
(3aR,6aR)-N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-1-methyl-hexahydropyrrolo
[3,4-b]pyrrole-5(1H)-carboxamide;
(3aS,6aS)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-
methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;
(3aR,6aR)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-7-
methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide;
(3aS,6aS)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin
-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide; and
(3aR,6aR)-N-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin
-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide,
and/or at least one pharmaceutically acceptable salt thereof.

4. The method of claim 3, wherein the cancer is chosen from lung cancer, especially non small cell lung cancer, head and neck cancer, colorectal cancer, pharynx cancer, epidermoid cancer, and pancreatic cancer.

5. The method of claim 3, further comprising administering to said subject thereof an effective amount of an anti-cancer agent, wherein said anti-cancer agent is different from said at least one compound of claim 1, and/or at least one pharmaceutically acceptable salt thereof.

6. A method of inhibiting over-expression and/or over-activity of epidermal growth factor receptor comprising contacting epidermal growth factor receptor with an effective amount of at

least one compound of claim 1, and/or at least one pharmaceutically acceptable salt thereof.

7. A use of the compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof in the preparation of a medicine for treating cancer.

8. The use of Claim 7 wherein the cancer is chosen from lung cancer, especially non small cell lung cancer, head and neck cancer, colorectal cancer, pharynx cancer, epidermoid cancer, and pancreatic cancer.

9. The at least one compound and/or at least one pharmaceutically acceptable salt thereof according to claim 1 for inhibiting over-expression and/or over-activity of epidermal growth factor receptor or for treating cancer responsive to inhibition of overexpression and/or overactivity of epidermal growth factor receptor.

10. The at least one compound and/or at least one pharmaceutically acceptable salt thereof according to claim 9, wherein the cancer is chosen from lung cancer, especially non small cell lung cancer, head and neck cancer, colorectal cancer, pharynx cancer, epidermoid cancer, and pancreatic cancer.

Claims

1. The compound

(3 aR,6aR)-N-(4-(3 -ethynylphenylamino)-7-methoxyquinazolin-6-yl)- 1 -methyl-hexahydropyrrolo [3,4-b]pyrrole-5(lH)-carboxamide;

and/or at least one pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and the compound

(3 aR,6aR)-N-(4-(3 -ethynylphenylamino)-7-methoxyquinazolin-6-yl)- 1 -methyl-hexahydropyrrolo [3 ,4-b]pyrrole-5(1 H)-carboxamide;

and/or at least one pharmaceutically acceptable salt thereof.

3. A compound (3 aR,6aR)-N-(4-(3 -ethynylphenylamino)-7-methoxyquinazolin-6-yl)- 1 -methyl-hexahydropyrrolo [3 ,4-b]pyrrole-5(1 H)-carboxamide and/or at least one pharmaceutically acceptable salt thereof for use in the treatment of cancer responsive to inhibition of overexpression and/or overactivity of epidermal growth factor receptor.

4. The compound and/or at least one pharmaceutically acceptable salt thereof for use according to claim 3, wherein the cancer is chosen from lung cancer, especially non small cell lung cancer, head and neck cancer, colorectal cancer, pharynx cancer, epidermoid cancer, and pancreatic cancer.

5. The compound and/or at least one pharmaceutically acceptable salt thereof for use according to claim 3, further comprising an effective amount of an anti-cancer agent, wherein said anti-cancer agent is different from said at least one compound of claim 1, and/or at least one pharmaceutically acceptable salt thereof.

6. A compound (3 aR,6aR)-N-(4-(3 -ethynylphenylamino)-7-methoxyquinazolin-6-yl)-1 -methyl-hexahydropyrrolo [3 ,4-b]pyrrole-5(1 H)-carboxamide and/or at least one pharmaceutically acceptable salt thereof for use in the inhibition of over-expression and/or over-activity of epidermal growth factor receptor comprising contacting epidermal growth factor receptor with an effective amount of at least one compound of claim 1, and/or at least one pharmaceutically acceptable salt thereof.

7. A use of the compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof in the preparation of a medicine for treating cancer.

8. The use of Claim 7 wherein the cancer is chosen from lung cancer, especially non small cell lung cancer, head and neck cancer, colorectal cancer, pharynx cancer, epidermoid cancer, and pancreatic cancer.

9. The compound and/or at least one pharmaceutically acceptable salt thereof according to claim 1 for inhibiting over-expression and/or over-activity of epidermal growth factor receptor or for treating cancer responsive to inhibition of overexpression and/or overactivity of epidermal growth factor receptor.

10. The compound and/or at least one pharmaceutically acceptable salt thereof according to claim 9, wherein the cancer is chosen from lung cancer, especially non small cell lung cancer, head and neck cancer, colorectal cancer, pharynx cancer, epidermoid cancer, and pancreatic cancer.